Department of Ophthalmology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Am J Perinatol. 2012 Nov;29(10):827-31. doi: 10.1055/s-0032-1321495. Epub 2012 Jul 6.
To study the incidence of treated retinopathy of prematurity (ROP) using the revised U.S. screening guidelines, the rate of missed treatment, and unfavorable anatomic outcomes over a period of 2 years.
We reviewed the admission records of premature patients treated at our hospital from September 2008 to August 2010. Any baby born with a gestational age (GA) of less than 30 weeks or a birth body weight (BW) of less than 2000 g was included in this study. The ROP screening followed the revised U.S. screening guidelines as presented in 2006. The indications of treatment for ROP were threshold disease as defined by the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity study and type 1 prethreshold ROP as defined by the Early Treatment for Retinopathy of Prematurity Randomized Trial study.
There were 385 infants who were examined for ROP screening during this period. Nineteen babies (35 eyes) fit the treatment criteria and received treatment. The incidence of treatment-demand ROP was 4.9% (19/385). Four babies had a birth BW >1500 g (4/19; 21%). Seventeen babies received treatment during their first admission and two babies received treatment during outpatient follow-up. No baby missed timely treatment. Three eyes progressed to stage 4/5 after receiving intravitreal bevacizumab treatment. The success rate after primary bevacizumab was 91% (30/33 eyes).
The incidence of treatment-demanding ROP using revised U.S. screening criteria was 4.9%. Teamwork and cooperation are very important to ensure that the highest-quality care possible is provided to patients in a timely manner.
使用修订后的美国筛查指南研究治疗性早产儿视网膜病变（ROP）的发生率、治疗遗漏率以及 2 年内不利的解剖学结局。
我们回顾了 2008 年 9 月至 2010 年 8 月在我院治疗的早产儿的入院记录。本研究纳入了胎龄（GA）<30 周或出生体重（BW）<2000g 的所有婴儿。ROP 筛查遵循 2006 年提出的修订后的美国筛查指南。ROP 治疗的指征为多中心冷冻治疗早产儿视网膜病变试验定义的阈值病变和早期治疗早产儿视网膜病变随机试验定义的 1 型阈前 ROP。
在此期间，有 385 名婴儿接受了 ROP 筛查检查。有 19 名婴儿（35 只眼）符合治疗标准并接受了治疗。治疗需求 ROP 的发生率为 4.9%（19/385）。有 4 名婴儿的出生 BW>1500g（4/19；21%）。17 名婴儿在首次入院期间接受了治疗，2 名婴儿在门诊随访期间接受了治疗。没有婴儿错过及时治疗。3 只眼在接受玻璃体内贝伐单抗治疗后进展至 4/5 期。初次贝伐单抗治疗的成功率为 91%（30/33 只眼）。
使用修订后的美国筛查标准，治疗性 ROP 的发生率为 4.9%。团队合作对于确保及时为患者提供尽可能高质量的护理非常重要。
